Clinical Edge Journal Scan

Radiological progression persists despite limited radiological damage in RA patients treated to target of remission


 

Key clinical point: Despite limited radiological damage, rapid radiological progression (RRP) still occurred in about 1 of 5 patients in a real-world cohort of patients with rheumatoid arthritis (RA) treated to the target of remission. RRP was most strongly predicted by baseline erosive disease.

Major finding: Most radiological damage occurred in the first year of treatment vs subsequent 5 years of follow-up (median Sharp/van der Heijde score, 2.0 vs 3.0). Despite achieving low disease activity, almost 18.8% of the patients developed RRP within 6 months, and the number of patients with erosive disease increased from 16% at baseline to 58% at 6 years. The erosive disease was the strongest predictor of RRP (odds ratio, 8.8; P less than .001).

Study details: Findings are from the observational DREAM remission induction cohort involving 219 patients diagnosed with RA who had at least 1 radiograph of hands and feet at baseline and at least 1 additional pair of radiographs during 6 years of follow-up and were treated to the target of remission.

Disclosures: No external funding and/or potential conflicts of interest were reported.

Source: Versteeg GA et al. Scand J Rheumatol. 2021 Jun 21. doi: 10.1080/03009742.2021.1917161 .

Recommended Reading

Clinical Edge Commentary: RA July 2021
MDedge Rheumatology
Vertebral fractures still a risk with low-dose oral glucocorticoids for RA
MDedge Rheumatology
COVID-19 vaccine hesitancy still weighs heavy for some rheumatic disease patients
MDedge Rheumatology
Commentary: RA August 2021
MDedge Rheumatology
RA: No significant change in efficacy and safety after adalimumab to CT-P17 switch
MDedge Rheumatology
Bazedoxifene effectively prevents glucocorticoid-induced bone loss in RA
MDedge Rheumatology
RA: Systemic glucocorticoids most beneficial for pain reduction shortly after initiation
MDedge Rheumatology
Sarilumab shows long-term promise in RA refractory to TNF inhibitors
MDedge Rheumatology
RA: Lower swollen joint count at 5 years is a predictor of unacceptable pain
MDedge Rheumatology
Screening for sarcopenia warranted in middle-aged and older adults with RA
MDedge Rheumatology